1
Alejandro A Aruffo, Diane Hollenbaugh, Anthony W Siadak, Karen K Berry, Linda Harris, Barbara A Thorne, Jurgen Bajorath: Antibodies against human CD40. Bristol Myers Squibb Co, Christopher A Klein, Audrey F Sher, April 18, 2000: US06051228 (81 worldwide citation)

The Applicants have discovered a novel antibody, more specifically a chimerized anti-human CD40 monoclonal antibody, which blocks the interaction between gp39 and CD40. The anti-CD40 antibodies of the present invention are effective in modulating humoral immune responses against T cell-dependent ant ...


2
Christian P Larsen, Alejandro A Aruffo, Diane L Hollenbaugh, Peter S Linsley, Jeffrey A Ledbetter, Thomas C Pearson: Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith. Bristol Myers Squibb Company, Emory University, Mandel & Adriano, June 29, 1999: US05916560 (73 worldwide citation)

The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand an ...


3
Alejandro A Aruffo, Peter S Linsley, Jeffrey A Ledbetter, Nitin K Damle, H Perry Fell Jr: Mixed specificity fusion proteins. Bristol Myers Squibb Company, Joseph M Sorrentino, January 20, 1998: US05709859 (69 worldwide citation)

Mixed specificity fusion proteins capable of binding to cellular adhesion molecules have been produced. The fusion proteins contain a polypeptide region, such as an IgG constant region, operatively attached to at least two binding regions each of which corresponds to either an extracellular domain o ...


4
Peter S Linsley, Mark A Kay, Christopher B Wilson, Jeffrey Ledbetter, Alejandro A Aruffo, Diane L Hollenbaugh: Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand. Bristol Myers Squibb Company, Mandel & Adriano, November 30, 1999: US05993800 (37 worldwide citation)

The invention provides a method for enhancing the expression of a gene of interest by a cell, the cell (a) comprises a recombinant nucleic acid sequence encoding and (b) is capable of expressing the gene of interest, the method comprising contacting the cell with an amount of a soluble CTLA4 molecul ...


5
Anthony W Siadak, Diane L Hollenbaugh, Lisa K Gilliland, Marcia L Gordon, Jurgen Bajorath, Alejandro A Aruffo: Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy. Bristol Myers Squibb Company, Christopher A Klein, Brian W Poor, Joseph M Sorrentino, March 2, 1999: US05876950 (34 worldwide citation)

The present invention provides monoclonal antibodies, antigen binding fragment and recombinant binding proteins specific for human gp39. These antibodies are specific for at least eight different epitopes on gp39. Hybridomas secreting specific antibodies which bind to these epitopes are also provide ...


6
Alain Martel, Jacques Banville, Alejandro A Aruffo: Sulfated .alpha.-glycolipid derivatives as cell adhesion inhibitors. Bristol Myers Squibb Company, Aldo A Algieri, September 2, 1997: US05663151 (29 worldwide citation)

There is provided novel sulfated .alpha.-glycolipid compounds of the formula ##STR1## wherein R is an acyl residue of a fatty acid;


7
Alejandro A Aruffo, Diane Hollenbaugh, Anthony W Siadak, Karen K Berry, Linda Harris, Barbara A Thorne, Jurgen Bajorath, William D Huse, Herren Wu, Jeffry D Watkins: Antibodies against human CD40. Joan E Switzer, November 6, 2001: US06312693 (21 worldwide citation)

The Applicants have discovered humanized anti-human CD40 antibodies which block the interaction between gp39 and CD40. The anti-CD40 antibodies of the present invention are effective in modulating humoral immune responses against T cell-dependent antigens, collagen induced arthritis, and skin transp ...


8
Alejandro A Aruffo, Jeffrey A Ledbetter, Ivan Stamenkovic, Randolph Noelle: Inhibiting B cell activation with soluble CD40 or fusion proteins thereof. Bristol Myers Squibb Company, Joan E Switzer, April 23, 2002: US06376459 (18 worldwide citation)

The present invention relates to a counter-receptor, termed CD40CR, for the CD40 B-cell antigen, and to soluble ligands for this receptor, including fusion molecules comprising at least a portion of CD40 protein. It is based, at least in part, on the discovery that a soluble CD40/immunoglobulin fusi ...


9
Alejandro A Aruffo, N Jan Chalupny, Lieping Chen, Robert S Mittler, Walter W Shuford, Anthony W Siadak: Methods and compositions for immunomodulation. Bristol Myers Squibb Co, Townsend and Townsend and Crew, April 3, 2001: US06210669 (15 worldwide citation)

The instant invention discloses the unexpected result that two anti-4-1BB monoclonal antibodies can inhibit both primary and secondary humoral responses to at least T-cell dependent antigens in vivo. Such antibodies provide a novel approach to immunosuppression and cancer therapy in vivo.


10
Alejandro A Aruffo, Jeffrey A Ledbetter, Ivan Stamenkovic, Randolph Noelle: CD40 receptor ligands. Bristol Myers Squibb Company, Joan E Switzer, October 29, 2002: US06472510 (13 worldwide citation)

The present invention relates to a counter-receptor, termed CD40CR, for the CD40 B-cell antigen, and to soluble ligands for this receptor, including fusion molecules comprising at least a portion of CD40 protein. It is based, at least in part, on the discovery that a soluble CD40/immunoglobulin fusi ...